BCRX Dividend: BioCryst Pharmaceuticals Inc Yield Insights

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	599	450	331	270	157	17
Revenue Growth (YoY)	45%	36%	23%	72%	824%	-65%
Cost of Revenue	15	12	4	6	7	1
Gross Profit	584	438	326	264	149	16
Selling, General & Admin	333	266	213	159	118	67
Research & Development	174	174	215	253	208	123
Operating Expenses	508	440	428	412	327	190
Other Non Operating Income (Expenses)	2	--	--	--	--	--
Pretax Income	-6	-86	-226	-244	-181	-182
Income Tax Expense	2	1	0	2	2	--
Net Income	-8	-88	-226	-247	-184	-182
Net Income Growth	-94%	-61%	-9%	34%	1%	69%
Shares Outstanding (Diluted)	219.88	206.69	192.19	185.9	179.1	167.3
Shares Change (YoY)	6%	8%	3%	4%	7%	45%
EPS (Diluted)	-0.04	-0.43	-1.17	-1.33	-1.03	-1.09
EPS Growth	-92%	-64%	-11%	28.99%	-6%	16%
Free Cash Flow	33	-53	-97	-163	-144	-135
Free Cash Flow Per Share	0.15	-0.25	-0.5	-0.87	-0.8	-0.8
Gross Margin	97.49%	97.33%	98.48%	97.77%	94.9%	94.11%
Operating Margin	12.68%	-0.44%	-30.81%	-54.81%	-112.73%	-1,023.52%
Profit Margin	-1.33%	-19.55%	-68.27%	-91.48%	-117.19%	-1,070.58%
Free Cash Flow Margin	5.5%	-11.77%	-29.3%	-60.37%	-91.71%	-794.11%
EBITDA	77	-1	-101	-147	-177	-174
EBITDA Margin	12.85%	-0.22%	-30.51%	-54.44%	-112.73%	-1,023.52%
D&A For EBITDA	1	1	1	1	0	0
EBIT	76	-2	-102	-148	-177	-174
EBIT Margin	12.68%	-0.44%	-30.81%	-54.81%	-112.73%	-1,023.52%
Effective Tax Rate	-33.33%	-1.16%	0%	-0.81%	-1.1%	--

BioCryst Pharmaceuticals Inc (BCRX) Price